Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05284747 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Study acronym: EVOLVE-MI
StatusActive, Not Recruiting
PhasePhase 4
SponsorAmgen
Started2022-10-26
View on ClinicalTrials.gov ↗
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).

Amendment record

Amended 44 times since 2022-03-09; most recent filed 2025-10-03. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2025-10-03
Amendment Study Status, Contacts/Locations v44
2024-11-13
Amendment Study Status, Study Design v43
2024-05-09
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v42
2024-04-24
Amendment Study Status, Contacts/Locations v41
2024-03-27
Amendment Study Status, Contacts/Locations v40
2024-02-28
Amendment Study Status, Contacts/Locations v39
2024-02-23
Amendment Study Status, Contacts/Locations v38
2024-02-15
Amendment Study Status, Contacts/Locations v37
2024-02-07
Amendment Study Status, Contacts/Locations v36
2024-01-10
Amendment Study Status, Study Design v35
2024-01-10
Amendment Study Status, Contacts/Locations v34
2024-01-03
Amendment Study Status, Contacts/Locations v33
2023-12-14
Amendment Study Status, Contacts/Locations v32
2023-12-07
Amendment Study Status, Contacts/Locations v31
2023-11-15
Amendment Study Status v30
2023-11-08
Amendment Study Status, Contacts/Locations v29
2023-10-26
Amendment Study Status, Contacts/Locations v28
2023-10-18
Amendment Study Status, Contacts/Locations v27
2023-10-12
Amendment Study Status v26
2023-10-12
Amendment Study Status, Contacts/Locations v25
2023-09-13
Amendment Study Status, Contacts/Locations v24
2023-09-06
Amendment Study Status v23
2023-08-30
Amendment Study Status, Contacts/Locations v22
2023-08-23
Amendment Study Status, Contacts/Locations v21
2023-08-02
Amendment Study Status, Contacts/Locations v20
2023-07-19
Amendment Study Status, Contacts/Locations v19
2023-07-12
Amendment Study Status, Contacts/Locations v18
2023-07-05
Amendment Study Status, Contacts/Locations v17
2023-06-28
Amendment Study Status, Contacts/Locations v16
2023-05-31
Amendment Study Status, Contacts/Locations v15
2023-05-24
Amendment Study Status, Contacts/Locations v14
2023-05-17
Amendment Study Status, Contacts/Locations v13
2023-05-12
Amendment Study Status, Outcome Measures, Eligibility, Contacts/Locations v12
2023-04-26
Amendment Study Status, Contacts/Locations v11
2023-04-19
Amendment Study Status, Contacts/Locations v10
2023-04-05
Amendment Study Status, Contacts/Locations v9
2022-12-21
Amendment Study Status, Contacts/Locations v8
2022-12-14
Amendment Study Status, Contacts/Locations v7
2022-12-07
Amendment Study Status, Contacts/Locations v6
2022-11-21
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5
2022-09-27
Amendment Study Status v4
2022-08-11
Amendment Study Status v3
2022-06-06
Amendment Study Status, Outcome Measures v2
2022-05-11
Amendment Study Status v1
2022-03-09
Original filing
Trial Details
NCT Number NCT05284747
Lead Sponsor Amgen
Collaborators: Colorado Prevention Center
Conditions Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Enrollment 6,019 participants
Start Date 2022-10-26
Primary Completion 2027-05-29 (estimated)
Study Completion 2027-05-29 (estimated)
Updated on ClinicalTrials.gov 2025-10-06